The United Kingdom has been investing in precision oncology for years now and it is becoming more prevalent. The NHS provides funding for precision oncology research in order to improve care for cancer patients. This includes the development of new drugs and treatments, as well as high-tech imaging techniques and genetic analysis. One example of this could be the NIHR Manchester Biomedical Research Centre which is hosted by Manchester University NHS Foundation Trust & The University of Manchester.

The promise of personalized medicine is that it will enhance patient treatment and ultimately benefit society significantly. Fully individualized medicine development is a process that has already begun and will continue in the upcoming years, but it is obvious that the initial stages of this journey will hinge on identifying scientifically sound biomarkers and developing these accurate clinical treatment plans.